Optimal glycemic control remains a cornerstone of diabetes management, but cardiovascular safety often dictates therapeutic choices. Clinicians routinely evaluate long-acting basal analogs when oral agents fail to achieve targets. Recent evidence comparing insulin degludec versus glargine provides vital clarity regarding long-term cardiovascular outcomes and survival. Randomized controlled trials offer gold-standard evidence, yet their strict exclusion criteria frequently omit the everyday patients seen in routine consultation. Consequently, modern pharmacoepidemiology uses target trial emulation to evaluate therapeutic regimens across broad, unselected populations.

Bridging the Gap Between Randomized Trials and Clinical Reality

The DEVOTE trial previously established that insulin degludec is non-inferior to insulin glargine for major adverse cardiovascular events. Furthermore, DEVOTE confirmed significant reductions in severe nocturnal hypoglycemia among high-risk individuals. However, randomized trials inevitably enroll highly curated cohorts with intensive monitoring, leaving practicing clinicians uncertain about broader generalizability. In daily practice, patients often present with multiple comorbidities, advanced age, fluctuating adherence, and variable renal function. Therefore, real-world comparative effectiveness research is essential to validate trial observations. Target trial emulation designs specifically address this gap by applying prospective protocol principles to observational healthcare databases. By defining an explicit protocol for a hypothetical target trial, investigators eliminate immortal time bias and minimize confounding. Consequently, researchers can accurately evaluate whether the cardiovascular benefits observed in rigid trials persist across standard outpatient clinics. Sweden maintains comprehensive nationwide health registers that capture granular biometric data, prescriptions, hospital admissions, and vital statistics. Thus, evaluating long-term insulin therapy in this setting yields robust insights into treatment trajectories and clinical outcomes.

Target Trial Emulation of Insulin Degludec Versus Glargine

To evaluate comparative cardiovascular outcomes, investigators leveraged nationwide Swedish health registries, including the National Diabetes Register. The researchers tracked individuals with type 2 diabetes who initiated either insulin degludec or insulin glargine between 2012 and 2022. Importantly, the study team implemented two complementary analytical cohorts to maximize clinical relevance. First, they constructed a trial-eligible emulation cohort that mirrored the strict criteria of the DEVOTE trial. Second, they developed a trial-ineligible cohort representing individuals routinely excluded from trials due to clinical complexities or differing baseline risk profiles. Among 96,731 identified individuals, exactly 44,890 met the predefined eligibility criteria for the primary analysis. The investigators designated three-point major adverse cardiovascular events, comprising non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, as the primary outcome. In addition, secondary outcomes tracked individual cardiovascular components, incident heart failure hospitalizations, and all-cause mortality. To adjust for dynamic confounders, the researchers applied longitudinal targeted minimum loss-based estimation. Consequently, this sophisticated methodology produced highly reliable, doubly robust causal effect estimates.

Cardiovascular and Mortality Findings in Trial-Eligible Cohorts

In the trial-eligible emulation cohort, the findings closely mirrored the primary conclusions of the original DEVOTE trial. Specifically, initiation of insulin degludec resulted in a similar risk of major adverse cardiovascular events compared with insulin glargine. The risk ratio for three-point MACE reached 1.10 with a 95% confidence interval spanning from 0.91 to 1.34, showing no statistically significant difference. This neutrality reaffirms that both basal insulin analogs offer equivalent vascular safety in patients who match clinical trial demographics. However, a striking and unexpected divergence emerged regarding total survival. Patients initiating insulin degludec experienced a statistically significant 25% reduction in all-cause mortality compared to those prescribed insulin glargine. The corresponding risk ratio stood at 0.75 with a tight 95% confidence interval between 0.62 and 0.92. Moreover, this survival benefit occurred despite equivalence in composite atherothrombotic endpoints. Clinicians frequently observe that non-cardiovascular deaths contribute substantially to overall mortality in elderly diabetes populations. Therefore, the pronounced survival advantage associated with degludec highlights physiological benefits extending beyond classic atherosclerotic plaque events.

Substantial Survival and Vascular Advantages in Routine Practice

While the trial-eligible cohort confirmed cardiovascular neutrality, the trial-ineligible emulation cohort revealed broader therapeutic superiorities. Indeed, this cohort represents the true clinical majority encountered in day-to-day medical practice. Within this routine care population, degludec initiation was associated with a significant 20% reduction in primary major adverse cardiovascular events. The observed risk ratio was 0.80, supported by a 95% confidence interval from 0.67 to 0.95. Furthermore, degludec demonstrated consistent advantages across nearly all individual secondary endpoints. Patients treated with degludec showed significantly reduced rates of cardiovascular mortality, non-fatal stroke, and heart failure hospitalizations. In addition, all-cause mortality decreased significantly in this cohort, aligning with the survival benefit seen in trial-eligible participants. Several pathophysiological factors likely explain these favorable outcomes in vulnerable patients. Degludec possesses a prolonged half-life exceeding 25 hours, producing an exceptionally flat and stable pharmacodynamic profile. Consequently, it minimizes day-to-day glycemic variability and substantially reduces nocturnal hypoglycemia. Because severe hypoglycemia triggers cardiac arrhythmias and endothelial inflammation, minimizing hypoglycemic episodes directly protects fragile cardiovascular systems.

Translational Implications for Clinical Practice in India

These real-world findings hold immense significance for healthcare practitioners managing diabetes in India. South Asian populations exhibit accelerated cardiovascular disease risk, presenting with premature coronary atherosclerosis, distinct visceral adiposity, and severe metabolic dysfunction. Furthermore, Indian clinicians manage a high volume of elderly patients with advanced disease, renal impairment, and variable meal timings. In such settings, hypoglycemia represents a major barrier to effective insulin titration and adherence. The reduced glycemic variability and lower hypoglycemia rates inherent to insulin degludec offer a distinct therapeutic advantage. When patients miss exact injection timings, the ultra-long duration of degludec provides dosing flexibility without precipitating erratic blood glucose spikes or nocturnal lows. Moreover, the observed reductions in heart failure admissions and stroke in routine practice cohorts address prevalent complications in Indian diabetics. Although acquisition cost remains an important consideration in resource-constrained practices, optimizing basal insulin selection can prevent costly acute hospitalizations. Thus, incorporating degludec into clinical algorithms provides measurable long-term health benefits, improving overall longevity and cardiovascular resilience.

Why did degludec demonstrate superior mortality outcomes over glargine in this nationwide registry study?

The survival advantage associated with insulin degludec primarily stems from its unique pharmacokinetic stability and prolonged duration of action. Unlike earlier basal analogs, degludec forms soluble multi-hexamers that release monomers slowly, creating a remarkably flat profile. Consequently, patients experience substantially fewer episodes of severe and nocturnal hypoglycemia. Because severe hypoglycemia precipitates lethal cardiac arrhythmias, sympathetic surges, and systemic inflammation, minimizing glycemic fluctuations preserves endothelial function and significantly reduces all-cause mortality.

How do the findings in trial-ineligible patients influence real-world clinical decision-making?

Clinical trials typically exclude patients with complex multimorbidity, advanced chronic kidney disease, or extreme frailty. However, this study demonstrated that trial-ineligible individuals derived substantial clinical advantages from degludec, including significant reductions in stroke, heart failure, and major cardiovascular events. Therefore, clinicians should not hesitate to prescribe ultra-long-acting basal insulin to medically vulnerable patients. These findings reassure practitioners that real-world individuals outside standard clinical trial criteria obtain meaningful cardioprotective and survival benefits.

What advantages does target trial emulation offer over traditional observational cohort studies?

Target trial emulation applies rigorous clinical trial principles directly to observational datasets, effectively preventing prevalent user bias and immortal time bias. By aligning the baseline time zero with the precise moment of insulin initiation, investigators avoid misclassifying exposure status. Furthermore, utilizing advanced statistical methods like longitudinal targeted minimum loss-based estimation adjusts for time-varying confounders. As a result, observational registries can generate causal inferences that closely replicate randomized controlled trials while evaluating broad, diverse patient populations.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Nyström T et al. Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial-Eligible and Ineligible Populations: A DEVOTE-Inspired Target Trial Emulation Using the Swedish National Diabetes Register. Diabetes Obes Metab. 2026 Oct 19. doi: 10.1111/dom.71429. PMID: 42897087.

Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. doi:10.1056/NEJMoa1615692.

American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1):S1-S270.